참고문헌
- Amaral JA, De-Franco MT, Carneiro-Sampaio MMS, et al. (2002). Antienteropathogenic Escherichia coli immunoglobulin Y isolated from eggs laid by immunized Leghorn chickens. Res Vet Sci, 72, 229-34. https://doi.org/10.1053/rvsc.2002.0551
- Almasan A, Ashkenazi A (2003). po2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev, 14, 337-48. https://doi.org/10.1016/S1359-6101(03)00029-7
- Almeida CMC, Kanashiro MM, Filho FBR, et al. (1998). Development of snake antivenom antibodies in chickens and their purification from yolk. Vet Rec, 143, 579-84. https://doi.org/10.1136/vr.143.21.579
- Ashkenazi A, Dixit VM. (1999). Apoptosis control by death and decoy receptors. Curr Opin Chem Biol, 11, 255-60. https://doi.org/10.1016/S0955-0674(99)80034-9
- Ashkenazi A. (2008). Targeting the extrinisic apoptosis pathway in cancer cytokine growth factor. Cytokine Growth Factor Rev, 19, 325-31. https://doi.org/10.1016/j.cytogfr.2008.04.001
- Bodmer JL, Holler N, Reynard S, et al. (2000). Trail receptor-2 signals apoptosis through FADD and caspase-8. J Nat Cell Biol, 2, 241-3. https://doi.org/10.1038/35008667
- Bollen LS, Hau J (1996). Chicken eggs in polyclonal antibody production. Scand J Lab Anim Sci, 23, 85-91.
- Chalghoumi R, Beckers Y, Portetelle D, et al. (2009). Hen egg yolk antibodies (IgY), production and use for passive immunization against bacterial enteric infections in chicken: a review. Biotechnol Agron Soc Environ, 13, 295-308.
- Chen KF, Chen HL, Liu CY, et al (2012). Dovitinib sencitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Biochem Pharmacol, 83, 769-77. https://doi.org/10.1016/j.bcp.2011.12.035
- Dias da Silva W, Tambourgi DV (2010). IgY: A promising antibody for use in immunodiagnostic and in immunotherapy. Vet Immunol Immunopathol, 135, 173-80. https://doi.org/10.1016/j.vetimm.2009.12.011
- Di-Lonardo M, Marcante L, Poggiali F, et al (2001). Egg yolk antibodies against the E7 oncogenic protein of human papillomavirus type 16. Arch Virol, 146, 117-25. https://doi.org/10.1007/s007050170195
- Du YW, Chen JG, Bai HL, et al (2011). A novel agonistic anti-human death receptor 5 monoclonal antibody with tumoricidal activity induces caspase- and mitochondrial-dependent apoptosis in human leukemia Jurkat cells. Cancer Biother Radiopharm, 26, 143-52. https://doi.org/10.1089/cbr.2010.0827
- Guo Y, Chen C, Zheng Y, et al (2005). A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent Cell Death Dis, 280, 41940-52.
- Hau J, Westergaard JG, Svendsen P, et al (1980). Comparison between pregnancy-associated murine protein-2 (PAMP-2) and human pregnancy specific beta-1-glycoprotein (SP-1). J Reprod Fertil, 60, 115-9. https://doi.org/10.1530/jrf.0.0600115
- Hau J, Westergaard JG, Svendsen P, et al (1981). Comparison of pregnancy-associated protein-1 and human pregnancy zone protein. J Reprod Immunol, 3, 341-9. https://doi.org/10.1016/0165-0378(81)90050-4
- Ichikawa K, Liu W, Zhao L, et al (2010). Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med, 7, 954-60.
- Jo M, Kim TH, Seol DW, et al (2000). Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med, 6, 564-67. https://doi.org/10.1038/75045
- Kelley RF, Totpal K, Lindstrom SH, et al (2005). Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem, 280, 2205-12. https://doi.org/10.1074/jbc.M410660200
- Kimberley FC, Screaton GR (2004). Following a TRAIL: update on a ligand and its five receptors. Cell Res, 14, 359-72. https://doi.org/10.1038/sj.cr.7290236
- Kischkel FC, Lawrence DA, Chuntharapai A, et al (2000). Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity, 12, 611-20. https://doi.org/10.1016/S1074-7613(00)80212-5
- Lawrence D, Shahrokh Z, Marsters S, et al. (2001). Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med, 7, 383-5. https://doi.org/10.1038/86397
- Lebedeva IV, Su ZZ, Sarkar D, et al (2003). Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Sem Cancer Biol, 13, 169-78. https://doi.org/10.1016/S1044-579X(02)00134-7
- LeBlanc HN, Ashkenazi A (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ, 10, 66-75. https://doi.org/10.1038/sj.cdd.4401187
- Lemamy GJ, Roger P, Mani JC, et al. (1999). Highaffinity antibodies from hen's-egg yolk against human mannose-6 phosphate/insulin-like growth-factor-II receptor (MGP/IGFII-R): Characterization and potential use in clinical cancer studies. Int J Cancer, 80, 896-902. https://doi.org/10.1002/(SICI)1097-0215(19990315)80:6<896::AID-IJC16>3.0.CO;2-J
- Leslie GA, Clem LW (1969). Phylogeny of immunoglobulin structure and functions. III. Immunoglobulins of the chicken. J Exp Med, 130, 1337-52. https://doi.org/10.1084/jem.130.6.1337
- Ozoren N, Kim K, Burns TF, et al (2000). The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res, 60, 6259-65.
- Salcedo TW, Alderson RF, Basu S, et al (2002). TRM-1, a fully human TRAIL-R1 agonistic monoclonal antibody, displays in vitro and in vivo anti-tumor activity. Proc Annu Meet Am Assoc Cancer Res, 43, 856.
- Sarker SA, Casswall TH, Juneja FL, et al (2001). Randomised, placebo-controlled, clinical trial of hyperimmunised chicken egg yolk immunoglobulin (HEY) in children with rotavirus diarrhoea. J Pediat Gastroenterol Nutr, 32, 19-25. https://doi.org/10.1097/00005176-200101000-00009
- Schade R, Hlinak A, Marburger A, et al (1997). Advantages of using egg yolk antibodies in the life sciences: the results of five studies. ATLA-Altern Lab Anim, 25, 555-86.
- Shargh SA, Sakizli M, Khalaj V, et al (2014). Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor. Med Oncol, 31, 250. https://doi.org/10.1007/s12032-014-0250-y
- Sprick MR, Weigand MA, Rieser E, et al (2000). FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity, 12, 599-609. https://doi.org/10.1016/S1074-7613(00)80211-3
- Svendsen L, O'Brien D, Stodulski G, et al (1994). Use of chickens and exploitation of egg yolk antibody production. In: Welfare and Science (Bunyan J ed). Royal Society of Medicine Press, London, 324-7.
- Thompson CB. (1995). Apoptosis in the pathogenesis and treatment of disease. Science, 267, 1456-62. https://doi.org/10.1126/science.7878464
- Tini M, Jewell UR, Camenish G. (2002). Generation and application of chicken egg-yolk antibodies. Comp Biochem Physiol, 131, 569-74. https://doi.org/10.1016/S1095-6433(01)00508-6
- Walczak H, Miller RE, Ariail K, et al (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 5, 157-63. https://doi.org/10.1038/5517
- Xiang H, Reyes AE, Eppler S, et al (2013). Death receptor 5 agonistic antibody PRO 95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection. Cancer Chemother Pharmacol, 75, 1-11.